🔗 Share this article

Given that the United States proceeds with sweeping revisions to its vaccination guidelines, one figure appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by expressing skepticism about coronavirus shots during the pandemic and has concentrated on possible fatalities following Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Schedule

Health officials planned to reveal major revisions to the pediatric vaccination calendar recently, aligning the US with the Danish immunization schedule, sources say – a major change that would put the US out of alignment with much of the international standard with insufficient data for benefit. The announcement has been pushed back until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is listed to address the audience at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon dismantling already-approved immunizations at the FDA.

The new acting director has frequently advocated for halting some childhood shot schedules in the US to become more like Denmark, a society with comprehensive healthcare and a number of inhabitants approximately the population of Wisconsin’s.

To date comments, she has continued to focus on vaccines – typically the domain of Dr. Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Expertise

Høeg has little discernible experience in medication creation, regulation or management, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a large organization. She is not an expert in pharmaceutical oversight.”

Previous commissioners of CBER would “grasp regulatory frameworks and the science of drug development”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who headed the center have had.”

This division has an enormous range of responsibilities at the agency, the former commissioner pointed out.

“The public just focuses on the new drug program, but the generic program clears a multitude of generic medications. There’s a biologic copycat branch, OTC medication office and more, and all of those must be supervised,” Dr. Woodcock explained. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a substantial management aspect to the role, which supervises more than 5,000 staff members. “It is a huge management job, if you do it right,” the former official concluded.

Official Statement and Disputed Programs

When asked about questions about Høeg’s fitness for the role and whether this appointment signifies more teamwork among FDA leaders on immunizations, a press secretary stated that the “concerns rely on incorrect presumptions”.

“This background aligns with the functions of her role,” the official explained, noting the time Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s controversial priority voucher program, a contentious rapid medication authorization process that allegedly concerned her predecessors. “How are these drugs being selected for this fast-track system? Who is making the calls?” Howard questioned. “There’s a lot of secrecy happening at the agency right now.”

In general, he stated, “the FDA looks to be trending towards laxer rules of pharmaceuticals, aside from vaccines.”

Documented History on Immunizations

With immunizations, Dr. Høeg has a more documented, if concerning, past, some experts observe. She published a study using unconfirmed volunteer-provided data to assess the incidence of heart inflammation after Covid immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are riskier than they are.

Included in her “desired changes” for the current administration included revising guidelines for recently developed shots and discontinuing “unnecessary” vaccines, she remarked post-election on a audio program. At the FDA, Dr. Høeg has reportedly proposed excluding teenage boys from receiving Covid vaccines.

“She’s an complete dogmatist who starts off with her beliefs and works backwards to fit the evidence in a extremely disingenuous, untruthful way,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow contrarians, {like|